临床实践中治疗试验筛选与治疗指征:MACK-3,一种诊断纤维化性NASH的新型血液检测
研究基于三个中心846例经活检证实的NAFLD患者,随机分为推导集与验证集,开发并验证了结合HOMA、AST和CK18的新型血液检测MACK-3,用于诊断纤维化性NASH(NASH且NAFLD活动度评分≥4并晚期纤维化F≥2)。验证集中MACK-3的AUROC显著高于血液纤维化检测,在灰区使用肝活检时分类准确率达93.3%。
要点
- MACK-3由HOMA、AST和CK18组成,用于诊断纤维化性NASH。
- 验证集中MACK-3的AUROC为0.847±0.030,显著高于BARD、NFS和FIB4。
- 灰区(36.0%患者)经肝活检,MACK-3分类准确率93.3%,敏感性90.0%,特异性94.2%。
核心结论
- 新型血液检测MACK-3能准确诊断纤维化性NASH,将有助于患者筛查和纳入NAFLD治疗试验,并在药物获批后识别可从治疗中获益的患者。
研究设计与样本
- 研究纳入来自三个中心(昂热、尼斯、安特卫普)的846例经活检证实的NAFLD患者,随机分为推导集和验证集。
主要发现
- 血液纤维化检测BARD、NFS和FIB4对纤维化性NASH的准确性较差,AUROC分别为0.566±0.023、0.654±0.023、0.732±0.021。
- 在推导集中,纤维化性NASH由AST、HOMA和CK18独立预测,三者组合为新型血液检测MACK-3,并计算了90%敏感性和95%特异性切点。
- 在验证集中,MACK-3的AUROC为0.847±0.030,显著高于血液纤维化检测(P≤0.002)。
- 在两个切点之间的灰区(36.0%的患者)使用肝活检,MACK-3诊断纤维化性NASH的准确性极好:93.3%患者分类正确,敏感性90.0%,特异性94.2%,阳性预测值81.8%,阴性预测值97.0%。
关键数值与推荐
- 纤维化性NASH定义为NASH且NAFLD活动度评分≥4并晚期纤维化(F≥2)。
- MACK-3的90%敏感性切点和95%特异性切点被计算用于诊断纤维化性NASH。
临床怎么用
- MACK-3将促进患者筛查和纳入NAFLD治疗试验,并能在治疗获批后识别可从治疗中获益的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The composite histological endpoint comprising nonalcoholic steatohepatitis (NASH) and NAFLD activity score ≥4 and advanced fibrosis (F ≥ 2) ("fibrotic NASH") is becoming an important diagnostic target in NAFLD: it is currently used to select patients for inclusion in phase III therapeutic trials and will ultimately be used to indicate treatment in clinical practice once the new drugs are approved. AIM: To develop a new blood test specifically dedicated for this new diagnostic target of interest. METHODS: Eight Hundred and forty-six biopsy-proven NAFLD patients from three centres (Angers, Nice, Antwerp) were randomised into derivation and validation sets. RESULTS: The blood fibrosis tests BARD, NFS and FIB4 had poor accuracy for fibrotic NASH with respective AUROC: 0.566 ± 0.023, 0.654 ± 0.023, 0.732 ± 0.021. In the derivation set, fibrotic NASH was independently predicted by AST, HOMA and CK18; all three were combined in the new blood test MACK-3 (hoMa, Ast, CK18) for which 90% sensitivity and 95% specificity cut-offs were calculated. In the validation set, MACK-3 had a significantly higher AUROC (0.847 ± 0.030, P ≤ 0.002) than blood fibrosis tests. Using liver biopsy in the grey zone between the two cut-offs (36.0% of the patients), MACK-3 provided excellent accuracy for the diagnosis of fibrotic NASH with 93.3% well-classified patients, sensitivity: 90.0%, specificity: 94.2%, positive predictive value: 81.8% and negative predictive value: 97.0%. CONCLUSION: The new blood test MACK-3 accurately diagnoses fibrotic NASH. This new test will facilitate patient screening and inclusion in NAFLD therapeutic trials and will enable the identification of patients who will benefit from the treatments once approved.
引用
- Boursier J, Anty R, Vonghia L, et al. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther. 2018. PMID: 29577364. doi:10.1111/apt.14621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。